Multicentre, Open-label, Phase I/IIa Clinical Study of an Immunoprotective Therapeutic Vaccine Candidate (VAC-3S) in Human Immunodeficiency Virus Type 1 (HIV-1) Chronically Infected Patients Virologically Controlled on Antiretroviral Therapy (ART) Who Rose an Immune Response to VAC-3S During IVVAC-3S/P1

Trial Profile

Multicentre, Open-label, Phase I/IIa Clinical Study of an Immunoprotective Therapeutic Vaccine Candidate (VAC-3S) in Human Immunodeficiency Virus Type 1 (HIV-1) Chronically Infected Patients Virologically Controlled on Antiretroviral Therapy (ART) Who Rose an Immune Response to VAC-3S During IVVAC-3S/P1

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs VAC 3S (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors InnaVirVax
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jun 2016 The primary endpoint timeframe has been changed from (Day 0 to week 48) to (Day 0 to week 16).
    • 16 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top